论文部分内容阅读
目的:分析重组人血管内皮抑制素联合顺铂化疗方案治疗老年晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法:选取82例老年晚期NSCLC患者作为研究对象,应用随机数字表将患者分为观察组和对照组,每组各41例。对照组患者给予含顺铂的两药化疗方案进行治疗,观察组患者在对照组疗法的基础上加用重组人血管内皮抑制素治疗。对两组患者的临床疗效、临床有效率(CRR)、临床受益率(CBR)进行评价。对两组患者治疗前后的Karnofsky评分、血清癌胚抗原(CEA)水平变化进行观察和比较。对两组患者进行随访,对患者的总生存期(OS)和疾病进展时间(TTP)进行观察和比较。对两组患者治疗期间不良反应发生率进行观察和比较。结果:观察组患者CRR和CBR均显著高于对照组,差异均有统计学意义(P<0.05)。两组患者治疗前、后Karnofsky评分的上升幅度和血清CEA水平的下降幅度的差异无统计学意义(P>0.05)。观察组患者和对照组患者的OS中位数估计值分别为16.720月和14.590月,TTP中位数估计值分别为6.260月和4.770月,两组患者OS和TTP中位数估计值的差异均有统计学意义(P<0.05)。两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:在老年晚期NSCLC患者的治疗中,在含顺铂治疗方案基础上加用重组人血管内皮抑制素进行治疗,能够提高患者的临床受益和治疗有效率,延长患者的生存期,改善患者的预后,且未增加不良反应的发生率。
Objective: To analyze the efficacy and safety of recombinant human endostatin combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 82 elderly patients with advanced NSCLC were enrolled in this study. Patients were divided into observation group and control group using random number table, with 41 cases in each group. Patients in the control group were treated with cisplatin-based two-drug chemotherapy regimen. Patients in the observation group were treated with recombinant human endostatin on the basis of the control group. The clinical efficacy, clinical response rate (CRR) and clinical benefit rate (CBR) of two groups of patients were evaluated. Karnofsky score and serum carcinoembryonic antigen (CEA) levels before and after treatment were observed and compared between the two groups. The two groups of patients were followed up, the overall survival (OS) and disease progression time (TTP) were observed and compared. The incidence of adverse reactions in the two groups during treatment were observed and compared. Results: The CRR and CBR in the observation group were significantly higher than those in the control group, the differences were statistically significant (P <0.05). There was no significant difference between the increase of Karnofsky score and the decline of serum CEA level in both groups before and after treatment (P> 0.05). The OS median of the observation group and the control group were respectively 16.20 months and 14.590 months. The estimated median TTP were 6. 260 months and 4.770 months, respectively, and the difference between the two groups was statistically significant There was statistical significance (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: In the treatment of elderly patients with advanced NSCLC, treatment with cisplatin combined with recombinant human endostatin can improve the patient’s clinical benefit and treatment efficiency, prolong the survival of patients and improve the patient’s Prognosis, and did not increase the incidence of adverse reactions.